background elderly patients patients multiple morbidities patients reduced general condition standard treatment inoperable lung cancer nsclc consists chemotherapy radiation therapy associated extremely poor prognosis investigated feasibility toxicity efficacy radiotherapy concurrent chemotherapy using vinorelbine plus cisplatin carboplatin nsclc patients risk treatment complications patients methods total NUMBER patients women NUMBER men median age NUMBER years locally advanced functionally inoperable pulmonary carcinomas recurrent lung cancer postoperative macroscopic residual tumors r2 increased risk treatment complications performance status cardiac renal pulmonary failure marked pretherapeutic weight loss age years received NUMBER mg vinorelbine m2 body surface area bsa days NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER plus cisplatin NUMBER bsa patients carboplatin NUMBER bsa NUMBER patients days conventionally fractionated radiotherapy tumor regions irradiated doses NUMBER gy NUMBER isodose potentially affected lymph nodes received doses NUMBER NUMBER gy NUMBER isodose results briefly NUMBER NUMBER patients successfully completed radiation therapy NUMBER received cycles vinorelbine plus cycles cisplatin carboplatin hematotoxic effects included grade iii leukocytopenia n NUMBER grade iii thrombocytopenia n NUMBER grade iv thrombocytopenia n NUMBER effects consisted peripheral neuropathy grade iii n NUMBER esophagitis grade iv n NUMBER severe pneumonitis did occur patients pneumonia radiochemotherapy NUMBER patients NUMBER exhibited complete n NUMBER partial response n NUMBER chemoradiation nonresponders stable n NUMBER progressive disease n NUMBER survival rates plus standard deviations follows survival NUMBER NUMBER survival NUMBER NUMBER survival NUMBER NUMBER median survival time NUMBER months NUMBER months NUMBER confidence interval ci median survival NUMBER months NUMBER months NUMBER ci median time NUMBER months conclusion conventionally fractionated radiochemotherapy vinorelbine plus platinum derivative feasible patients nsclc increased risk treatment complications compared patient populations described literature survival rates achieved concurrent radiochemotherapy appear better achieved radiotherapy non small cell NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER year NUMBER year NUMBER year progression free follow NUMBER NUMBER mg m2 mg m2